← All trials
NCT04574713
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2020
- Primary completion
- May 15, 2024
- Completion date
- May 15, 2024
- First posted
- Oct 5, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 450
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Norwegian University of Science and TechnologyCollaborator
- University Hospital of North NorwayCollaborator
- Oslo Metropolitan UniversityCollaborator
- Sorlandet Hospital HFCollaborator
- University of BergenCollaborator
- Nordland HospitalCollaborator
- University of OsloCollaborator
- University of TartuCollaborator
- Molde University CollegeCollaborator
- Norwegian University of Science and TechnologyStudy director
- Norwegian University of Science and TechnologyOverall official - principal investigator
- St Olavs Hospital, Dept Neurology & Clinical NeurophysiologyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.